Results 41 to 50 of about 46,300 (164)

Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches

Biology, 2020
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are secreted from the gut upon nutrient stimulation and regulate postprandial metabolism.
Geke Aline Boer, Jens Juul Holst
doaj   +1 more source

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): a short‐term cost‐effectiveness analysis in the UK setting [PDF]

, 2018
Aim: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.
ADVANCE Collaborative Group, American Diabetes Association Consensus Panel, Anderson, Bagust, Bagust, Billings, Blak, Boye, Chubb, Control Group, Currie, Donnelly, Duckworth, Evans, Forst, Gaede, Gaede, Giugliano, Grandy, Hammer, Holman, Hunt, Hunt, Hunt, Inzucchi, Ismail-Beigi, Johnston, Lee, Matza, McCabe, Meneghini, Mezquita-Raya, National Institute for Health and Care Excellence (NICE), Nauck, Parekh, Peyrot, Peyrot, Ridderstråle, Russell-Jones, Shi, Stettler, The Forum for Injection Technique (FIT), TREND-UK, UK Prospective Diabetes Study (UKPDS) Group, UK Prospective Diabetes Study (UKPDS) Group, Walz, Wang, Wild   +47 more
core   +1 more source

Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery

Frontiers in Drug Delivery
GLP-1 receptor agonists ((GLP-1 RAs) are currently receiving a lot of attention because of their impact in diabetes, weight loss and other areas. While GLP-1 RAs in injectable form are highly efficacious, further work is required to develop oral versions
R. R. C. New, R. R. C. New, M. Bogus, G. N. Travers, U. Hahn, A. Vaiceliunaite, M. Burnet, J. H. Wang, H. Wen   +8 more
doaj   +1 more source

Use and effectiveness of dapagliflozin in routine clinical practice. An Italian multicenter retrospective study [PDF]

, 2018
In randomized controlled trials (RCTs), sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to confer glycaemic and extra-glycaemic benefits.
Avogaro A, Baldi I, Bottigliengo D, Consoli A, DARWIN-T2D network., Fadini GP, Giaccari A, Sesti G, Zatti G   +8 more
core   +2 more sources

Some doubts about the mantra on the deleterious cardiovascular effects of sulfonylureas [PDF]

, 2017
[No abstract ...
Prudente, Sabrina, Trischitta, Vincenzo
core   +1 more source

The comparative efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists on metabolic benefits in T2DM patients: a systematic review and network meta-analysis

European Journal of Medical Research
Background SGLT-2 inhibitors and GLP-1 receptor agonists exhibit metabolic benefits on improving obesity, diabetes, hypertension and hyperlipidemia, but the differences between them remain unclear.
Jingkai Tong, Nana Li, Fang Hu, Yingying Yue   +3 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in Chronic Kidney Disease: Mechanisms and Clinical Perspectives

Kidney Medicine
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin-based therapies initially developed for the management of type 2 diabetes. In addition to improving glycemic control and promoting weight loss, these agents have demonstrated cardiovascular ...
Mackenzi Meier, Jamessa Cummings, Mohammed Abdelsaid, Jose Feliciano, Jazmin Eusebe, Hanna Stirn, Maha Coucha   +6 more
doaj   +1 more source

Glucagon-like peptide analogues for type 2 diabetes mellitus : systematic review and meta-analysis [PDF]

, 2010
Background Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis ...
Shyangdan, D. (Deepson), Royle, Pamela, Clar, C., Sharma, Pawana, Waugh, Norman   +4 more
core   +4 more sources

Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials

BMC Gastroenterology
Background Metabolic dysfunction-associated fatty liver disease (MAFLD) affects up to 30% of the global population, yet effective pharmacological treatments remain limited. This systematic review and meta-analysis evaluated the efficacy of GLP-1 receptor
Surtika Tamilwanan, Zoriah Aziz, Lim Yan Rong, Ahmad Naoras Bitar, Raghdaa Hamdan Al Zarzour, Salah A. Alshehade   +5 more
doaj   +1 more source

Diabetic kidney disease. new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "the natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function" [PDF]

, 2019
Recent epidemiological studies have disclosed heterogeneity in diabetic kidney disease (DKD). In addition to the classical albuminuric phenotype, two new phenotypes have emerged, i.e., “nonalbuminuric renal impairment” and “progressive renal decline ...
Barutta, Federica, De Nicola, Luca, Di Paolo, Salvatore, Gesualdo, Loreto, Natali, Andrea, Penno, Giuseppe, Pugliese, Giuseppe, Reboldi, Gianpaolo   +7 more
core   +1 more source